Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-11-29Clinical Trial Update: A Double-Blind Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epilepsy [Phase 3]
A Phase 3 double-blind trial assessing cannabidiol as add-on therapy for refractory epilepsy; efficacy and safety results are not provided i…
-
FDA approval · 2023-11-22FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Bionpharma Inc.)
FDA approved a supplemental application for divalproex sodium submitted by Bionpharma Inc. under an ANDA.
-
FDA approval · 2023-11-22FDA Approved: DIAZEPAM — Supplemental Application (Sunrise Pharmaceutical, Inc.)
The FDA approved a supplemental application for Diazepam submitted by Sunrise Pharmaceutical, Inc.
-
FDA approval · 2023-11-21FDA Approved: LEVETIRACETAM — Supplemental Application (Major Pharmaceuticals)
The FDA approved a supplemental application for levetiracetam from Major Pharmaceuticals under ANDA201157.
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: Measuring Blood Flow in the Brain After Epileptic Activity [Phase 2]
Phase 2 clinical trial update evaluating blood flow measurement in the brain following epileptic activity.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-11-17FDA Approved: TOPIRAMATE — Original Application (Dr. Reddys Laboratories Inc.)
FDA approves a generic version of Topiramate from Dr. Reddy's Laboratories Inc. through an Original Application (ANDA).
-
FDA approval · 2023-11-16FDA Approved: LEVETIRACETAM — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for levetiracetam from Fresenius Kabi USA, LLC under an ANDA.
-
CLINICAL_TRIALS trial_result · 2023-11-14Clinical Trial Update: Presurgical Motor Mapping With Transcranial Magnetic Stimulation (TMS) [NA]
Completed clinical trial evaluating presurgical motor mapping with transcranial magnetic stimulation (TMS) for epilepsy; results posted.
-
FDA approval · 2023-11-13FDA Approved: LACOSAMIDE — Original Application (Apotex Corp)
FDA approved Apotex Corp's original ANDA for lacosamide, authorizing a generic version of the anticonvulsant used to treat partial-onset sei…
-
CLINICAL_TRIALS trial_result · 2023-11-09Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy [Phase 3]
This Phase 3 trial evaluated the efficacy and safety of Brivaracetam in participants with epilepsy, including partial-onset seizures with or…
-
CLINICAL_TRIALS trial_result · 2023-11-01Clinical Trial Update: Manipulating and Optimizing Brain Rhythms for Enhancement of Sleep [NA]
A terminated clinical trial from Mayo Clinic investigating brain rhythm manipulation to enhance sleep, with posted results.
-
FDA approval · 2023-10-24FDA Approved: LEVETIRACETAM — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for levetiracetam from Amneal Pharmaceuticals LLC.
-
FDA approval · 2023-10-23FDA Approved: LEVETIRACETAM — Supplemental Application (Hisun Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for levetiracetam from Hisun Pharmaceuticals USA, Inc., resulting in approval of a generic produ…
-
FDA approval · 2023-10-23FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for divalproex sodium from Mylan Pharmaceuticals, indicating regulatory authorization for a generic …
-
FDA approval · 2023-10-20FDA Approved: OXCARBAZEPINE — Original Application (NorthStar RxLLC)
The FDA approved NorthStar RxLLC's original application for oxcarbazepine, a generic antiepileptic drug, for the treatment of partial-onset …
-
FDA approval · 2023-10-16FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for Vimpat (lacosamide) submitted by UCB, Inc., resulting in updated labeling for the product.
-
FDA approval · 2023-10-16FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc. The approval confirms the sponsor's supplemental …
-
FDA approval · 2023-10-13FDA Approved: FOSPHENYTOIN SODIUM — Original Application (Sagent Pharmaceuticals)
FDA approved an original generic application for fosphenytoin sodium, enabling a generic version of this anticonvulsant to be marketed by Sa…
-
EMA withdrawal · 2023-10-12EMA Withdrawn: Pregabalin Sandoz GmbH (pregabalin) — Sandoz GmbH
The EMA withdrew the Pregabalin Sandoz GmbH (pregabalin) product from the market, affecting indications in Anxiety Disorders and Epilepsy.
-
FDA approval · 2023-10-11FDA Approved: VALIUM — Supplemental Application (Roche Laboratories Inc.)
FDA approved a Supplemental Application for Valium (diazepam) from Roche Laboratories Inc., indicating an approved change or addition to the…
-
FDA approval · 2023-10-11FDA Approved: VIGABATRIN — Supplemental Application (Par Health USA, LLC)
FDA approved a supplemental application for Vigabatrin by Par Health USA, LLC.
-
CLINICAL_TRIALS trial_result · 2023-10-11Clinical Trial Update: Bioequivalence Study of Sodium Valproate and Valproic Acid Tablets [Phase 4]
A Phase 4 clinical trial update assessing bioequivalence between sodium valproate and valproic acid tablets for epilepsy.
-
FDA approval · 2023-10-06FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for divalproex sodium from Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2023-10-06FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved a supplemental application for divalproex sodium from Upsher-Smith Laboratories, LLC.
-
FDA approval · 2023-10-06FDA Approved: ESLICARBAZEPINE ACETATE — Original Application (Ascend Laboratories, LLC)
The FDA approved Ascend Laboratories, LLC's eslicarbazepine acetate as an original generic application. It is indicated as adjunctive therap…